{"id":49096,"date":"2022-10-03T18:01:49","date_gmt":"2022-10-03T16:01:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/"},"modified":"2022-10-03T18:01:49","modified_gmt":"2022-10-03T16:01:49","slug":"median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/","title":{"rendered":"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nThe Clinical Advisory Board includes world class physicians and academic leaders in the space of lung cancer\n<\/li>\n<li>\nThe Clinical Advisory Board will bring comprehensive expertise on Lung Cancer Screening to guide Median in the development of iBiopsy\u00ae LCS AI\/ML tech-based CADe\/CADx Software as Medical device.\n<\/li>\n<\/ul>\n<p>SOPHIA-ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221003005735\/en\/1343975\/5\/Median_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221003005735\/en\/1343975\/21\/Median_RGB.jpg\"><\/a><\/p>\n<p>\nMedian Technologies (Paris:ALMDT) announced today the formation of their Clinical Advisory Board (CAB) for iBiopsy\u00ae Lung Cancer Screening. This group of world class physicians brings comprehensive expertise in the space of Lung Cancer Screening to guide Median in the development of iBiopsy\u00ae LCS AI\/ML tech-based CADe\/CADx SaMD (software as medical device), which detects and characterizes lung cancer nodules in high risk populations, ultimately aimed at improving patient outcomes as well as clinical workflows.\n<\/p>\n<p>\n\u201c<i>We are privileged to have the opportunity to bring together this group of truly world-class physicians and academic leaders, who\u2019s expertise and invaluable insights will help guide our late stage development as we approach pivotal clinical studies towards regulatory approval, and beyond<\/i>\u201d said Thomas Bonnefont, iBiopsy\u00ae COO and CCO at Median.\n<\/p>\n<p>\n<i>\u201cI am pleased and honored to be working with this team of distinguished and highly accomplished clinicians, who\u2019s wealth of knowledge and experience will help Median deliver on optimizing the Lung Cancer Screening routine and saving patient lives.\u201d<\/i> said Yan Liu M.D., Chief Medical Officer of Median\n<\/p>\n<p>\nIntroducing the members of Clinical Advisory Board for Lung Cancer Screening (in alphabetical order):\n<\/p>\n<p class=\"bwmarginl1\">\n<b>Philippe Grenier<br \/>\n<br \/><\/b>Professor, Thoracic Radiologist and Head of the Artificial Intelligence project, Hopital Foch, Suresnes (France)\n<\/p>\n<p class=\"bwmarginl1\">\n<b>Francesco Grossi<br \/>\n<br \/><\/b>Director of the Division of Medical Oncology and Associate Professor at the University of Insubria, Varese (Italy)\n<\/p>\n<p class=\"bwmarginl1\">\n<b>Luis Seijo Maceiras<br \/>\n<br \/><\/b>Director of Pneumology Department \u2013 Clinica Universidad de Navarra, Madrid (Spain)\n<\/p>\n<p class=\"bwmarginl1\">\n<b>Carey Thomso<br \/>\n<br \/><\/b>Chair, Department of Medicine and Director, Multidisciplinary Thoracic Oncology and Lung Cancer Screening Program, Mount Auburn Hospital\/Beth Israel Lahey Health, Cambridge, Massachusetts (United States) &#8211; Associate Professor of Medicine at Harvard Medical School, Boston, Massachussets (United States)\n<\/p>\n<p class=\"bwmarginl1\">\n<b>Anil Vachani<br \/>\n<br \/><\/b>Director of Clinical Research, Section of Interventional Pulmonary and Thoracic Oncology, Penn Medicine, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia (United States)\n<\/p>\n<p class=\"bwmarginl1\">\n<b>David Yankelevitz<br \/>\n<br \/><\/b>Professor of Radiology and Director of the Lung Biopsy Service at the Icahn School of Medicine, Mount Sinai, New York City (USA)\n<\/p>\n<p class=\"bwmarginl1\">\n<b>Javier Zulueta<br \/>\n<br \/><\/b>Senior Faculty and Chief of the Division of Medicine (Pulmonary, Critical Care and Sleep Medicine) at Mount Sinai Morningside, Professor of Medicine, Icahn School of Medicine, Mount Sinai, New York City (USA)\n<\/p>\n<p>\n<b>About iBiopsy\u00ae:<\/b> iBiopsy\u00ae is based on the most advanced technologies in Artificial Intelligence (AI) and Data Science (DS), benefiting from Median\u2019s expertise in medical image processing. iBiopsy\u00ae targets the development of innovative AI\/ML-based Software as Medical Device, to be used in several indications for which there are unmet needs regarding early diagnosis, prognosis and treatment selection in the context of precision medicine. iBiopsy\u00ae currently focuses on lung cancer, liver cancer (HCC) and liver fibrosis (NASH).\n<\/p>\n<p>\n<strong>About Median Technologies:<\/strong><b> <\/b>Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy\u00ae, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.\n<\/p>\n<p>\nFounded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label \u201cInnovative company\u201d by the BPI and is listed on Euronext Growth market (Paris). FR0011049824\u2013 ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext\u00ae PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mediantechnologies.com%2F&amp;esheet=52934747&amp;newsitemid=20221003005735&amp;lan=en-US&amp;anchor=www.mediantechnologies.com&amp;index=1&amp;md5=a853ec1970ebf231148c7d403d9fc08c\" rel=\"nofollow noopener\" shape=\"rect\">www.mediantechnologies.com<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Median Technologies<\/b><br \/>Emmanuelle Leygues<br \/>\n<br \/>Head of Corporate Marketing &amp; Financial Communications<br \/>\n<br \/>+33 6 10 93 58 88<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#111;&#x3a;&#101;&#x6d;m&#x61;n&#117;&#x65;&#108;&#x6c;e&#x2e;&#x6c;&#101;&#x79;g&#x75;e&#115;&#x40;&#109;&#x65;d&#x69;a&#110;&#x74;&#101;&#x63;h&#110;&#x6f;&#108;&#x6f;g&#x69;e&#115;&#x2e;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x65;&#109;&#x6d;&#x61;n&#x75;&#101;l&#x6c;&#101;&#46;&#x6c;&#101;&#x79;&#x67;u&#x65;&#115;&#64;&#x6d;&#101;d&#x69;&#97;&#x6e;&#x74;&#101;&#x63;&#x68;n&#x6f;&#108;o&#x67;&#105;e&#x73;&#46;&#x63;&#x6f;m<\/a>\n<\/p>\n<p>\n<b>Press &#8211; ALIZE RP<\/b><br \/>Caroline Carmagnol<br \/>\n<br \/>+33 6 64 18 99 59<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;&#111;&#x3a;&#x6d;&#101;d&#x69;&#97;n&#x40;&#x61;&#108;i&#x7a;&#101;r&#x70;&#x2e;&#99;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;e&#x64;&#105;&#x61;&#110;&#x40;&#x61;l&#x69;&#122;&#x65;&#114;&#x70;&#46;c&#x6f;&#109;<\/a>\n<\/p>\n<p>\n<b>Investors &#8211; ACTIFIN<\/b><br \/>Ghislaine Gasparetto<br \/>\n<br \/>+33 6 21 10 49 24<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x67;&#103;&#x61;&#115;&#x70;&#97;&#x72;&#101;&#x74;&#116;&#x6f;&#64;&#x61;&#99;&#x74;&#105;&#x66;&#105;&#x6e;&#46;&#x66;&#114;\" rel=\"nofollow noopener\" shape=\"rect\">&#103;&#x67;a&#115;&#x70;a&#x72;&#x65;&#116;&#x74;o&#64;&#x61;c&#116;&#x69;&#102;&#x69;n&#46;&#x66;r<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Clinical Advisory Board includes world class physicians and academic leaders in the space of lung cancer The Clinical Advisory Board will bring comprehensive expertise on Lung Cancer Screening to guide Median in the development of iBiopsy\u00ae LCS AI\/ML tech-based CADe\/CADx Software as Medical device. SOPHIA-ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Median Technologies (Paris:ALMDT) announced today the &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49096","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The Clinical Advisory Board includes world class physicians and academic leaders in the space of lung cancer The Clinical Advisory Board will bring comprehensive expertise on Lung Cancer Screening to guide Median in the development of iBiopsy\u00ae LCS AI\/ML tech-based CADe\/CADx Software as Medical device. SOPHIA-ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Median Technologies (Paris:ALMDT) announced today the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-03T16:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221003005735\/en\/1343975\/21\/Median_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening\",\"datePublished\":\"2022-10-03T16:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/\"},\"wordCount\":721,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005735\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/\",\"name\":\"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005735\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"datePublished\":\"2022-10-03T16:01:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005735\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005735\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/","og_locale":"en_US","og_type":"article","og_title":"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening - Pharma Trend","og_description":"The Clinical Advisory Board includes world class physicians and academic leaders in the space of lung cancer The Clinical Advisory Board will bring comprehensive expertise on Lung Cancer Screening to guide Median in the development of iBiopsy\u00ae LCS AI\/ML tech-based CADe\/CADx Software as Medical device. SOPHIA-ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Median Technologies (Paris:ALMDT) announced today the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-03T16:01:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221003005735\/en\/1343975\/21\/Median_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening","datePublished":"2022-10-03T16:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/"},"wordCount":721,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221003005735\/en\/1343975\/21\/Median_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/","url":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/","name":"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221003005735\/en\/1343975\/21\/Median_RGB.jpg","datePublished":"2022-10-03T16:01:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221003005735\/en\/1343975\/21\/Median_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221003005735\/en\/1343975\/21\/Median_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-formation-of-clinical-advisory-board-for-ibiopsy-lung-cancer-screening\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy\u00ae Lung Cancer Screening"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49096"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49096\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}